We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma (GALACCTIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00924989
Recruitment Status : Completed
First Posted : June 19, 2009
Last Update Posted : July 12, 2013
Information provided by (Responsible Party):
Astellas Pharma Inc

June 17, 2009
June 19, 2009
July 12, 2013
September 2009
July 2012   (Final data collection date for primary outcome measure)
Overall survival of single agent OSI-906 versus placebo [ Time Frame: 33 months ]
Time from date of randomization until time of documented death
Overall survival of single agent OSI-906 vs placebo [ Time Frame: 24 months ]
Complete list of historical versions of study NCT00924989 on ClinicalTrials.gov Archive Site
  • Progression-free survival [ Time Frame: 24 months ]
    Time from randomization to disease progression based on RECIST version 1.1 or death due to any cause, whichever comes first
  • Disease control rate [ Time Frame: 24 months ]
    Proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD), based on RECIST criteria
  • Best overall response rate [ Time Frame: 24 months ]
    Proportion of patients with a best overall response of CR or PR based on RECIST criteria
  • Duration of response [ Time Frame: 24 months ]
    Time from date of the first documented response (CP/PR) to documented progression or death due to underlying cancer
  • Time to deterioration in Quality of Life [ Time Frame: 24 months ]
    Measured by European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires
  • Safety assessed via physical exams, vital signs, laboratory assessments, electrocardiograms, and adverse events [ Time Frame: 24 months ]
  • Progression-free survival [ Time Frame: 24 months ]
  • Disease control rate [ Time Frame: 24 months ]
  • Best overall response rate [ Time Frame: 24 months ]
  • Duration of response [ Time Frame: 24 months ]
  • Quality of Life [ Time Frame: 24 months ]
  • Safety profile [ Time Frame: 24 months ]
  • Pharmacokinetics (PK), Pharmacodynamics (PD) [ Time Frame: 24 months ]
Not Provided
Not Provided
A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug regimens
Patients will be randomized 2:1 to receive either single agent OSI-906 (Arm A) or placebo (Arm B) and will be stratified according to prior systemic cytotoxic chemotherapy for ACC, and Eastern Cooperative Oncology Group (ECOG) performance status, and use of >= 1 oral antihyperglycemic therapy at randomization
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Adrenocortical Carcinoma
  • Drug: OSI-906
    Administered orally
    Other Name: linsitinib
  • Other: Placebo
    Matching placebo administered orally
  • Experimental: Arm A: OSI-906
    150 mg twice daily
    Intervention: Drug: OSI-906
  • Placebo Comparator: Arm B: Placebo
    Matching placebo twice daily
    Intervention: Other: Placebo
Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. doi: 10.1016/S1470-2045(15)70081-1. Epub 2015 Mar 18.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
October 2012
July 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed adrenocortical carcinoma that is locally advanced or metastatic and not amenable to surgical resection.
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1).
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2
  • Predicted life expectancy >= 12 weeks.
  • At least 1 but no more than 2 prior drug regimens (including molecular targeted therapy, systemic cytotoxic chemotherapy, biologics, and/or vaccines) for locally advanced/metastatic ACC.
  • A minimum of 3 weeks must have elapsed between the end of prior treatment and randomization.
  • All patients must have received prior mitotane, either as neoadjuvant, adjuvant, or locally advanced/metastatic therapy.
  • Adjuvant and neoadjuvant mitotane therapy will not be counted as prior drug regimens or as systemic cytotoxic chemotherapy.
  • Prior radiation therapy is permitted provided patients have recovered from the acute, toxic effects of radiotherapy prior to randomization.
  • A minimum of 21 days must have elapsed between the end of radiotherapy and randomization.
  • Prior surgery is permitted provided that adequate wound healing has occurred prior to randomization.
  • Fasting glucose < = 150 mg/dL (8.3 mmol/L).
  • Adequate hematopoietic, hepatic, and renal function defined as follows: Neutrophil count >= 1.5 x 10^9 /L;
  • Platelet count >= 100 x 10^9 /L;
  • Bilirubin <= 1.5 x Upper Limit of Normal (ULN);
  • AST and ALT <= 2.5 x ULN, or <= 5 x ULN if patient has documented liver metastases or received prior mitotane therapy; and
  • Serum creatinine <= 1.5 x ULN or <= 2.0 x ULN if the patient has received prior cisplatin.
  • Patients, both males and females, with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must agree to practice effective contraceptive measures throughout the study.
  • Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to randomization.
  • Patients must provide verbal and written informed consent to participate in the study.
  • Radiologically-confirmed progressive disease within 6 months prior to randomization.
  • Concurrent use of non-insulinotropic oral antihyperglycemic therapy is permitted if the dose has been stable for >= 4 weeks at the time of randomization.

Exclusion Criteria:

  • Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring insulinotropic or insulin therapy.
  • Prior IGF-1R inhibitor therapy.
  • Malignancy other than ACC within the past 3 years. Exceptions: resected basal cell or squamous cell carcinoma of the skin; cured in situ cervical carcinoma; cured ductal carcinoma in situ of the breast; and/or cured superficial bladder cancer.
  • History of significant cardiovascular disease unless the disease is well-controlled.
  • Significant cardiac diseases includes second/third degree heart block; clinically significant ischemic heart disease; mean QTcF interval > 450 msec at screening;
  • poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea).
  • History of cerebrovascular accident (CVA) within 6 months prior to randomization or that resulted in ongoing neurologic instability.
  • Use of drugs that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing.
  • Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization) that would impair the ability of the patient to receive study drug.
  • History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent.
  • Pregnant or breast-feeding females.
  • Symptomatic brain metastases that are not stable, require steroids, are potentially life threatening, or that have required radiation within 28 days prior to randomization.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drug.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Australia,   Canada,   France,   Germany,   Italy,   Netherlands,   Poland,   United Kingdom,   United States
Belgium,   Brazil,   Sweden
2009-012820-97 ( EudraCT Number )
Not Provided
Not Provided
Astellas Pharma Inc
Astellas Pharma Inc
Not Provided
Study Director: Medical Director Astellas Pharma Global Development
Astellas Pharma Inc
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP